Servier to buy Day One Biopharmaceuticals for total equity value of $2.5 billion

Core Viewpoint - French drugmaker Servier is set to acquire Day One Biopharmaceuticals for approximately $2.5 billion, enhancing its portfolio in brain tumor treatments [1] Group 1: Acquisition Details - Servier will pay $21.50 per share in cash for Day One, which represents a 68% premium over Day One's last closing stock price [1] - The acquisition will provide Servier access to Ojemda, a treatment for pediatric low-grade glioma, the most common brain tumor in children [1] Group 2: Funding and Financial Implications - Servier plans to finance the transaction using existing cash and investments [1]